Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders (CoCo-Neurosciences) (CoCo-Neuro)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04362930 |
Recruitment Status : Unknown
Verified April 2020 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was: Recruiting
First Posted : April 27, 2020
Last Update Posted : May 13, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Neurologic Manifestations Psychiatric Disorders COVID-19 |

Study Type : | Observational |
Estimated Enrollment : | 2000 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders: An Observational Study of the Covid-19 Neurological and Psychiatric Manifestations |
Actual Study Start Date : | April 27, 2020 |
Estimated Primary Completion Date : | April 24, 2022 |
Estimated Study Completion Date : | April 24, 2022 |

Group/Cohort |
---|
Neurological and psychiatric impact of COVID-19
Covid-19 impact in neurological or psychiatric manifestations in patients with Covid-19 infection
|
Impact of Covid-19 in patients with neurological pathology
patients initially followed for a neurological or psychiatric pathology, suffering from a Covid-19 infection
|
- Central or peripheral neurological symptoms or psychiatric symptoms observed in patients with Covid-19 [ Time Frame: 12 months ]Frequency of central or peripheral neurological or psychiatric symptoms observed in patients with COVID-19
- Progression of pre-existing neurological or psychiatric pathologies [ Time Frame: 12 months ]Impact on neurological or psychiatric disease trajectories assessed by severity scores or subjective progression (improved, stable, impaired) during and after COVID-19 pathology in patients with pre-existing neurological and psychiatric diseases

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Age of 18 years or over
- Patient followed for a neurological or psychiatric pathology OR Patient consulting and presenting a neurological or psychiatric impairment AND
-
Presenting a COVID-19 infection defined by at least one of the following three criteria:
- Biological diagnosis by any method for direct detection of the virus (Covid-19 positive PCR) or recent infection (serology)
- Typical chest imaging (CT scan or X-ray) in an epidemic area
- Clinical-biological data leading to a strong suspicion of current or past Covid-19 infection
- Non-opposition of the participant, relative or guardian to the research
Exclusion Criteria:
- Patient under safety measure

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04362930
Contact: CECILE DELORME, MD | 142161802 ext +33 | cecile.delorme@aphp.fr | |
Contact: Jean-Christophe CORVOL, MD,PHD | 142161799 ext +33 | jean-christophe.corvol@aphp.fr |
France | |
Hôpital Pitié Salpétrière | Recruiting |
Paris, France, 75013 | |
Contact: cécile Delorme, MD 1 42 16 18 02 ext +33 cecile.delorme@aphp.fr |
Responsible Party: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT04362930 |
Other Study ID Numbers: |
APHP200525 |
First Posted: | April 27, 2020 Key Record Dates |
Last Update Posted: | May 13, 2020 |
Last Verified: | April 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 ENCEPHALOPATHY ENCEPHALITIS STROKE |
CONFUSION DELIRIUM DEPRESSION POST TRAUMATIC STRESS DISORDER |
COVID-19 Neurologic Manifestations Disease Mental Disorders Problem Behavior Pathologic Processes Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia |
Virus Diseases Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Behavioral Symptoms Nervous System Diseases |